Future of Drug Discovery7 Mar 2023

Membranotropic Drug Discovery - Alan Nafiev - #7

In this episode, we speak with Alan Nafiev, Co-Founder and CEO of ‘RECEPTOR.AI’, an Artificial Intelligence (AI)-drug discovery company focused on screening small drug molecule candidates against difficult-to-drug targets.

Alan gives some key insights into the history of Receptor AI, the company's successes and obstacles, and how Receptor AIs 'software as a service' (SaaS) and services are streamlining the drug discovery process for pharmaceutical and biotech companies. He also discusses how Receptor AIs technology can automate and customise drug discovery pipelines.

To conclude, Alan explains Receptor AIs plans for 2023 - branching into membranotropic drug discovery for cancer and cardiovascular diseases, through designing drugs against unique membrane environments.

Things mentioned:

Sergii Starosyla, Co-Founder and CTO of Receptor AI.
Semen Yesylevskyy, Co-Founder and CSO of Receptor AI.
Enamine, a partner to Receptor AI.

Additional Materials:

About Antiverse:

Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(18)

AI Statistical Programming for FDA Submissions - Louise Liu - #18

In this episode of Future of Drug Discovery, we speak with Louise Liu, Founder and CEO of Hill Research. The statistical programming behind an FDA submission is one of the slower steps in clinical dev...

20 Mai 25min

Rahmad Akbar - Frontiers of AI Antibody Design (FODD #17)

This episode is a discussion between ⁠Rahmad Akbar, Senior Data Scientist in Antibody Design at Novo Nordisk and Murat Tunaboylu⁠, Co-Founder and CEO of Antiverse⁠. You will learn: The impact anti...

3 Sep 202426min

Paul Essery and Murat Tunaboylu - Founding an AI Drug Discovery Start-Up (FODD #16)

This episode is a discussion between Paul Essery, Host of 'The Tech Business Podcast' and Murat Tunaboylu Co-Founder and CEO of Antiverse. You will learn: The CEO journey and how Antiverse was fou...

23 Jul 202414min

Inorganic Chemistry at the Frontier of Immunotherapy - Björn Schimmöller - #15

In this episode, we speak with ⁠⁠Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.Host: ⁠⁠Mura...

17 Jan 202422min

AI, Automation and Drug Discovery - Ashwini Ghogare - #14

In this episode, we speak with ⁠Ashwini Ghogare⁠, Head of Artificial Intelligence and Automation in Drug Discovery at ⁠MilliporeSigma⁠, the Global Science and Technology Group at ⁠Merck⁠.Host: ⁠Murat ...

11 Des 202326min

Unleashing the Power of Computational Biology - Ming 'Tommy' Tang - #13

In this talk, Murat speaks with Ming (Tommy) Tang, Director of Computational Biology at Immunitas Therapeutics, an immuno-oncology start-up developing novel therapeutics for patients with cancer. Tomm...

20 Okt 202333min

Digital Foundations For Rapid Healthcare Advancement - Nikhil Reddy Podduturi - #12

In this talk, Murat speaks with ⁠Nikhil Podduturi⁠, Head of Data Science at the Digital Lab of ⁠Boehringer Ingelheim⁠ - ⁠(BI X)⁠. Nikhil co-leads the laboratory and data science chapters at the BI X ...

6 Okt 202327min

Machine Learning Blueprints for Pharma Discovery Breakthroughs - Abhishek Pandey - #11

In this talk, Murat speaks with Abhishek Pandey, Principle Research Scientist and Pharma Discovery Group Lead at AbbVie. Abhishek currently leads RAIDERS, a Pharma Discovery group integrating machine ...

2 Mai 202327min